Dmytro Kharkov

New data from Bicara Therapeutics Inc. reveals long term outcomes from HPV negative HNSCC trial

New data from Bicara Therapeutics Inc. reveals long term outcomes from HPV negative HNSCC trial
Bicara reveals cancer trial update

Bicara Therapeutics Inc. released updated data showing durable responses at three years from its Phase 1/1b study evaluating ficerafusp alfa combined with pembrolizumab as a first line treatment for HPV negative recurrent or metastatic head and neck squamous cell carcinoma.

The company said that in approximately 90 patients across all three doses, deep initial responses were sustained and translated into durable long term outcomes, according to their latest dataset. This extended follow up provides evidence of potential clinical benefit in this hard to treat patient population.

Bicara previously announced deep and durable responses for ficerafusp alfa plus pembrolizumab in HPV negative HNSCC, according to a prior update. The company is also scheduled to present its first quarter 2026 financial results and a business update on May 11 via public webcast, as stated in a recent announcement. These developments follow continuing progress in its first line treatment programs.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.